165 related articles for article (PubMed ID: 18677056)
21. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
Davies A; Cifaldi MA; Segurado OG; Weisman MH
J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
Segal B; Rhodus NL; Patel K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
[TBL] [Abstract][Full Text] [Related]
24. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
Yamaguchi Y; Yamamoto K
Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
[TBL] [Abstract][Full Text] [Related]
25. [Recent progress in the treatment of rheumatoid arthritis].
Tanaka Y
Clin Calcium; 2012 Feb; 22(2):169-78. PubMed ID: 22298069
[TBL] [Abstract][Full Text] [Related]
26. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
Baker DE
Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
[TBL] [Abstract][Full Text] [Related]
27. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
28. Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
Matsuno H; Yoshida K; Ochiai A; Okamoto M
J Rheumatol; 2007 Dec; 34(12):2326-33. PubMed ID: 18050387
[TBL] [Abstract][Full Text] [Related]
29. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
Kapetanovic MC; Saxne T; Sjöholm A; Truedsson L; Jönsson G; Geborek P
Rheumatology (Oxford); 2006 Jan; 45(1):106-11. PubMed ID: 16287919
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
Akiyama Y; Mimura T
Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
[TBL] [Abstract][Full Text] [Related]
32. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.
DI Franco M; Paradiso M; Ceccarelli F; Scrivo R; Spinelli FR; Iannuccelli C; Valesini G
J Rheumatol; 2012 Jan; 39(1):41-5. PubMed ID: 22045840
[TBL] [Abstract][Full Text] [Related]
33. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
36. [Adalimumab (Humira)--efficacy in rheumatoid arthritis treatment with particular reference to working ability].
Grazio S
Reumatizam; 2008; 55(2):62-7. PubMed ID: 19024278
[TBL] [Abstract][Full Text] [Related]
37. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors].
Swierkot J; Madej M
Pol Merkur Lekarski; 2011 Apr; 30(178):283-8. PubMed ID: 21595176
[TBL] [Abstract][Full Text] [Related]
38. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
Tanaka Y
Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
[TBL] [Abstract][Full Text] [Related]
39. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma.
Sarzi-Puttini P; Atzeni F; Shoenfeld Y; Ferraccioli G
Autoimmun Rev; 2005 Mar; 4(3):153-61. PubMed ID: 15823501
[TBL] [Abstract][Full Text] [Related]
40. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
Keystone E; Freundlich B; Schiff M; Li J; Hooper M
J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]